Bioavailability Endpoints
Bioavailability Endpoints is a pharmacokinetic measurement serving as a quantitative indicator of the rate and extent to which an active drug ingredient or metabolite becomes available at the site of action, specifically used as a primary metric in bioequivalence studies to assess equivalence between formulations.
23
Publications
2K
Citations
141
Authors
53
Institutions
Publications per year
2017–2026
3
23
Juan J. Martínez Medina, Luciana G. Naso, Ana L. Pérez et al. · Journal of Inorganic Biochemistry · 2016 · 61 citations · Full text
1–5 of 23
141
1
h-index
National University of the Chaco Austral, Argentina
1 publications · 61 citations
1
h-index
1
h-index
1
h-index
Andalusian Institute of Agricultural and Fisheries Research and Training, Spain
1 publications · 89 citations
1
h-index
1–5 of 141
53

Oklahoma State University
Stillwater, United States
1 h-index
2 publications
94 citations
Siemens (Germany)
Munich, Germany
1 h-index
1 publications
47 citations
University of Wuppertal
Wuppertal, Germany
1 h-index
2 publications
28 citations
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan
1 h-index
6 publications
60 citations
Indian Council of Medical Research
New Delhi, India
1 h-index
1 publications
23 citations
University Hospital Frankfurt
Frankfurt am Main, Germany
1 h-index
3 publications
141 citations
Indiana University School of Medicine
Indianapolis, United States
1 h-index
1 publications
51 citations
Siemens Healthineers (Germany)
Forchheim, Germany
1 h-index
1 publications
47 citations
1–8 of 53
CPT · 2 publications · 29 citations
2
h-index
AJVR · 1 publications · 20 citations
1
h-index
1 publications · 89 citations
1
h-index
Repository · 1 publications · 23 citations
1
h-index
1 publications · 47 citations
1
h-index
1–5